The prognostic impact of lymphoma perforation in patients with primary gastrointestinal lymphoma - a single-center analysis

Standard

Harvard

APA

Vancouver

Bibtex

@article{10a8530599414cfda4e9cf7dfeafbd38,
title = "The prognostic impact of lymphoma perforation in patients with primary gastrointestinal lymphoma - a single-center analysis",
abstract = "Patients with primary gastrointestinal (GI) lymphoma are at risk of GI perforations. Therefore, we aimed to investigate the prognostic impact of non-traumatic GI perforations. 54 patients with a histologically confirmed diagnosis of primary GI lymphoma were included. Non-traumatic lymphoma perforation occurred in ten patients (19%). Perforations occurred only in patients with aggressive B-cell lymphoma. In patients with aggressive B-cell lymphoma, the median overall survival (mOS) was 52 months (95% CI 9.88-94.12) and 27 months (95% CI 0.00-135.48) in patients with and without GI perforation, respectively. The median progression-free survival (mPFS) was 30 months (95% CI 5.6-54.4) in patients with GI perforations. In patients without lymphoma perforation, mPFS was not reached. Both mOS and mPFS did not significantly differ. In conclusion, despite the need for emergency surgery and delay in lymphoma-directed treatment, lymphoma perforation did not negatively impact our study population's OS or PFS.",
author = "Franziska Modemann and Paymon Ahmadi and {von Kroge}, {Philipp H} and S{\"o}ren Weidemann and Carsten Bokemeyer and Judith Dierlamm and Walter Fiedler and Susanne Ghandili",
year = "2023",
month = aug,
day = "8",
doi = "10.1080/10428194.2023.2240921",
language = "English",
volume = "64",
pages = "1801--1810",
journal = "LEUKEMIA LYMPHOMA",
issn = "1042-8194",
publisher = "informa healthcare",
number = "11",

}

RIS

TY - JOUR

T1 - The prognostic impact of lymphoma perforation in patients with primary gastrointestinal lymphoma - a single-center analysis

AU - Modemann, Franziska

AU - Ahmadi, Paymon

AU - von Kroge, Philipp H

AU - Weidemann, Sören

AU - Bokemeyer, Carsten

AU - Dierlamm, Judith

AU - Fiedler, Walter

AU - Ghandili, Susanne

PY - 2023/8/8

Y1 - 2023/8/8

N2 - Patients with primary gastrointestinal (GI) lymphoma are at risk of GI perforations. Therefore, we aimed to investigate the prognostic impact of non-traumatic GI perforations. 54 patients with a histologically confirmed diagnosis of primary GI lymphoma were included. Non-traumatic lymphoma perforation occurred in ten patients (19%). Perforations occurred only in patients with aggressive B-cell lymphoma. In patients with aggressive B-cell lymphoma, the median overall survival (mOS) was 52 months (95% CI 9.88-94.12) and 27 months (95% CI 0.00-135.48) in patients with and without GI perforation, respectively. The median progression-free survival (mPFS) was 30 months (95% CI 5.6-54.4) in patients with GI perforations. In patients without lymphoma perforation, mPFS was not reached. Both mOS and mPFS did not significantly differ. In conclusion, despite the need for emergency surgery and delay in lymphoma-directed treatment, lymphoma perforation did not negatively impact our study population's OS or PFS.

AB - Patients with primary gastrointestinal (GI) lymphoma are at risk of GI perforations. Therefore, we aimed to investigate the prognostic impact of non-traumatic GI perforations. 54 patients with a histologically confirmed diagnosis of primary GI lymphoma were included. Non-traumatic lymphoma perforation occurred in ten patients (19%). Perforations occurred only in patients with aggressive B-cell lymphoma. In patients with aggressive B-cell lymphoma, the median overall survival (mOS) was 52 months (95% CI 9.88-94.12) and 27 months (95% CI 0.00-135.48) in patients with and without GI perforation, respectively. The median progression-free survival (mPFS) was 30 months (95% CI 5.6-54.4) in patients with GI perforations. In patients without lymphoma perforation, mPFS was not reached. Both mOS and mPFS did not significantly differ. In conclusion, despite the need for emergency surgery and delay in lymphoma-directed treatment, lymphoma perforation did not negatively impact our study population's OS or PFS.

U2 - 10.1080/10428194.2023.2240921

DO - 10.1080/10428194.2023.2240921

M3 - SCORING: Journal article

C2 - 37552203

VL - 64

SP - 1801

EP - 1810

JO - LEUKEMIA LYMPHOMA

JF - LEUKEMIA LYMPHOMA

SN - 1042-8194

IS - 11

ER -